PerkinElmer
check quantity

RediJect Bacterial Detection Fluorescent Imaging Probe (Control Dye)

XenoLight RediJect Bacterial Detection control dye is a non-reactive dye that can be used as a negative control when using the RediJect Bacterial Detection 750 fluorescent imaging probe. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
133399
154.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

RediJect Bacterial Detection fluorescent imaging control dye is a non-reactive dye used as a negative control when using the RediJect Bacterial Detection probe.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name XenoLight
Shipping Condition Blue Ice
Therapeutic Area Bacterial infection
Unit Size 1
Wave Length 750 nm
Resources, Events & More
  • All

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB